{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:13:50Z","timestamp":1790874830171,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weight gain and associated metabolic complications are increasingly prevalent among people with human immunodeficiency virus (PWH). Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are incretin-based therapies for diabetes and weight management that have been shown to result in substantial weight loss; however, studies of their effects in PWH are limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective single-center cohort study was conducted among PWH who were taking GLP-1RAs at the University of California, San Diego Owen Clinic between 1 February 2021 and 1 February 2023. Baseline clinical data were collected and changes in weight, body mass index (BMI), and hemoglobin A1C (A1C) before starting GLP-1RAs compared to the most recent clinic visit were calculated (with a minimum of 3 months follow-up time required). Logistic regression was performed to identify variables associated with &amp;gt;5% of total body weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 225 patients received on average 13 months of GLP-1RA therapy, with 85 (37.8%) achieving the maximum GLP-1RA dose. GLP-1RA therapy resulted, on average, in a weight loss of 5.4 kg, decrease in BMI by 1.8 kg\/m2, and decrease in A1C by 0.6%. In the multivariable analysis, higher baseline BMI (odds ratio [OR], 1.10 [95% confidence interval {CI}, 1.03\u20131.16]), treatment duration of GLP-1RA therapy &amp;gt;6 months (OR, 3.12 [95% CI, 1.49\u20136.49]), and use of tirzepatide (OR, 5.46 [95% CI, 1.44\u201320.76]) were significantly more likely to be associated with &amp;gt;5% weight loss.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Use of GLP-1RAs led to declines in weight, BMI, and A1C among PWH and offers an additional strategy to address weight gain and diabetes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciae151","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T08:53:57Z","timestamp":1710838437000},"page":"978-982","source":"Crossref","is-referenced-by-count":20,"title":["Glucagon-like Peptide 1 Receptor Agonists Promote Weight Loss Among People With HIV"],"prefix":"10.1093","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9170-6751","authenticated-orcid":false,"given":"Quynh","family":"Nguyen","sequence":"first","affiliation":[{"name":"School of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2184-0347","authenticated-orcid":false,"given":"Darcy","family":"Wooten","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Moreno","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Promer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amutha","family":"Rajagopal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kye","family":"Duren","sequence":"additional","affiliation":[{"name":"School of Medicine, University of California San Diego , California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Yin","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California , San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Hill","sequence":"additional","affiliation":[{"name":"Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California , San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"2024101519052067900_ciae151-B1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11904-020-00483-5","article-title":"Obesity and weight gain in persons with HIV","volume":"17","author":"Bailin","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024101519052067900_ciae151-B2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","author":"Antiretroviral Therapy Cohort Collaboration","year":"2008","journal-title":"Lancet"},{"key":"2024101519052067900_ciae151-B3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1056\/NEJMoa1507198","article-title":"A trial of early antiretrovirals and isoniazid preventive therapy in Africa","volume":"373","author":"TEMPRANO ANRS 12136 Study Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2024101519052067900_ciae151-B4","doi-asserted-by":"crossref","first-page":"e295","DOI":"10.1016\/S2352-3018(23)00028-0","article-title":"Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies","volume":"10","author":"Trickey","year":"2023","journal-title":"Lancet HIV"},{"key":"2024101519052067900_ciae151-B5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11904-022-00642-w","article-title":"Diabetes in HIV: the link to weight gain","volume":"20","author":"Bailin","year":"2023","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024101519052067900_ciae151-B6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11904-022-00600-6","article-title":"Metabolic consequences of antiretroviral therapy","volume":"19","author":"Diggins","year":"2022","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2024101519052067900_ciae151-B7","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J Int AIDS Soc"},{"key":"2024101519052067900_ciae151-B8","doi-asserted-by":"crossref","first-page":"5217","DOI":"10.24875\/AIDSRev.M20000036","article-title":"Weight gain in HIV-infected individuals using distinct antiretroviral drugs","volume":"22","author":"Buz\u00f3n-Mart\u00edn","year":"2020","journal-title":"AIDS Rev"},{"key":"2024101519052067900_ciae151-B9","doi-asserted-by":"crossref","first-page":"101412","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy\u2014a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"eClinicalMedicine"},{"key":"2024101519052067900_ciae151-B10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2024101519052067900_ciae151-B11","doi-asserted-by":"crossref","first-page":"e27047","DOI":"10.1097\/MD.0000000000027047","article-title":"Impact of switching to tenofovir alafenamide on weight gain as compared to maintaining a non-tenofovir alafenamide containing regimen","volume":"100","author":"Darnell","year":"2021","journal-title":"Medicine (Baltimore)"},{"key":"2024101519052067900_ciae151-B12","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"key":"2024101519052067900_ciae151-B13","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus\u2014a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"2024101519052067900_ciae151-B14","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11883-022-01041-7","article-title":"Glucagon-Like peptide 1 receptor agonists: a medication for obesity management","volume":"24","author":"Taha","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"2024101519052067900_ciae151-B15","doi-asserted-by":"crossref","first-page":"721135","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 receptor agonists: beyond their pancreatic effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol"},{"key":"2024101519052067900_ciae151-B16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"2024101519052067900_ciae151-B17","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/oby.23612","article-title":"Tirzepatide for the treatment of obesity: rationale and design of the SURMOUNT clinical development program","volume":"31","author":"Le Roux","year":"2023","journal-title":"Obesity"},{"key":"2024101519052067900_ciae151-B18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh","year":"2022","journal-title":"J Investig Med"},{"key":"2024101519052067900_ciae151-B19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.ajcnut.2023.04.017","article-title":"The weight-loss effect of GLP-1RAs glucagon-like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials","volume":"118","author":"Liu","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"2024101519052067900_ciae151-B20","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1007\/s12325-022-02153-x","article-title":"Efficacy of GLP-1 RA approved for weight management in patients with or without diabetes: a narrative review","volume":"39","author":"Jensterle","year":"2022","journal-title":"Adv Ther"},{"key":"2024101519052067900_ciae151-B21","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ajcnut.2023.07.007","article-title":"GLP-1 receptor agonists for weight loss in people without type 2 diabetes: what is the current evidence?","volume":"118","author":"Gluud","year":"2023","journal-title":"Am J Clin Nutr"},{"key":"2024101519052067900_ciae151-B22","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.pcd.2023.05.004","article-title":"Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: a non-randomized multicenter study from the titration phase","volume":"17","author":"Seijas-Amigo","year":"2023","journal-title":"Prim Care Diabetes"},{"issue":"Suppl 2","key":"2024101519052067900_ciae151-B23","first-page":"ofac492","article-title":"Do people living with HIV lose weight on GLP-1 agonist therapy?","volume":"9","author":"Tauhid","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024101519052067900_ciae151-B24","author":"Lloyd"},{"issue":"Suppl 2","key":"2024101519052067900_ciae151-B25","doi-asserted-by":"crossref","first-page":"ofad500.111","DOI":"10.1093\/ofid\/ofad500.111","article-title":"Effects of semaglutide on adipose tissue in HIV-associated lipohypertrophy","volume":"10","author":"McComsey","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae151\/57261822\/ciae151.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/4\/978\/59764817\/ciae151.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/79\/4\/978\/59764817\/ciae151.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T15:06:25Z","timestamp":1729004785000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/79\/4\/978\/7631407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,19]]},"published-print":{"date-parts":[[2024,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae151","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10,15]]},"published":{"date-parts":[[2024,3,19]]}}}